Abstract: A method of treating, preventing or ameliorating a disease or condition by inhibiting NR2B subunit containing NMDA receptors using a compound according to formula (I) or a pharmaceutically acceptable salt thereof:

Abstract: The present invention discloses a dysregulation of the KCNN3 gene and the protein products thereof in Alzheimer's disease patients and individuals being at risk of developing Alzheimer's disease. Based on this finding, the invention provides methods for diagnosing and prognosticating Alzheimer's disease in a subject, and for determining whether a subject is at increased risk of developing Alzheimer's disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating and preventing Alzheimer's disease and related neurodegenerative disorders using the KCNN3 gene and its corresponding gene products. Screening methods for modulating agents of neurodegenerative diseases are also disclosed.

Abstract: 1. Use of (v) a gene coding for a protein phosphatase 1 E having SEQ ID NO:1 or SEQ ID NO:2, and/or (vi) a transcription product of the gene coding for a protein phosphatase 1 E having SEQ ID NO:1 or SEQ ID NO:2, and/or (vii) a translation product of the gene coding for a protein phosphatase 1 E having SEQ ID NO:1 or SEQ ID NO:2, and/or (viii) a fragment, or derivative, or variant of (i) to (iii). for identifying or for testing agents for the treatment and/or prevention of neurodegenerative diseases.

Abstract: The use of 7-chloro-3-(5-dimethylaminomethyl-[1,2,4]oxadiazol-3-yl)-5methyl 4,5-dihydro-imidazol[1,5,-a][1,4]benzodiazepine-6-one or its pharmaceutically acceptable salt for treating various types of insomnia.

Abstract: The present invention discloses a dysregulation of the ADARB2 gene and the protein products thereof in Alzheimer's disease patients. Based on this finding, the invention provides methods for diagnosing and prognosticating Alzheimer's disease in a subject, and for determining whether a subject is at increased risk of developing Alzheimer's disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating and preventing Alzheimer's disease and related neurodegenerative disorders using the ADARB2 gene and its corresponding gene products. Screening methods for modulating agents of neurodegenerative diseases are also disclosed.

Abstract: The present invention discloses a dysregulation of the SLC39A11 gene and the protein products thereof in Alzheimer's disease patients. Based on this finding, the invention provides methods for diagnosing and prognosticating Alzheimer's disease in a subject, and for determining whether a subject is at increased risk of developing Alzheimer's disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating and preventing Alzheimer's disease and related neurodegenerative disorders using the SLC39A11 gene and its corresponding gene products. Screening methods for modulating agents of neurodegenerative diseases are also disclosed.

Abstract: The present invention claims an invertebrate animal that has been modified to express a set of genes, the set comprising the gene coding for a modified version of the gamma subunit of AMP-activated protein kinase (AMPKg). According to the invention, the animal displays an identifiable phenotype related to lipid metabolism and neurodegeneration. This animal provides a model of neurodegenerative diseases, particularly Alzheimer's disease, and may be useful for screening and testing modulating agents, substances and therapeutic compounds for neurodegenerative disorders.

Abstract: The present invention discloses a dysregulation of the SLC39A12 gene and the protein products thereof in Alzheimer's disease patients. Based on this finding, the invention provides methods for diagnosing and prognosticating Alzheimer's disease in a subject, and for determining whether a subject is at increased risk of developing Alzheimer's disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating and preventing Alzheimer's disease and related neurodegenerative disorders using the SLC39A12 gene and its corresponding gene products. Screening methods for modulating agents of neurodegenerative diseases are also disclosed.

Abstract: The present invention provides a protein encoded by the ATP2B gene and discloses the differential expression of the gene coding for ATP2B proteins in specific brain regions of Alzheimer's disease patients. Based on this finding, the invention provides a method for diagnosing or prognosticating Alzheimer's disease in a subject, or for determining whether a subject is at increased risk of developing Alzheimer's disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating or preventing Alzheimer's disease and related neurodegenerative disorders using the ATP2B gene and its corresponding gene products. A method of screening for modulating agents of neurodegenerative diseases is also disclosed.

Abstract: The present invention provides a novel protein encoded by the KCNC1 gene and discloses the differential expression of the gene KCNC1 coding for KCNC1 proteins in specific brain regions of Alzheimer's disease patients. Based on this finding, the invention provides a method for diagnosing or prognosticating Alzheimer's disease in a subject, or for determining whether a subject is at increased risk of developing Alzheimer's disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating or preventing Alzheimer's disease and related neurodegenerative disorders using the KCNC1 gene and its corresponding gene products. A method of screening for modulating agents of neurodegenerative diseases is also disclosed.

Abstract: The present invention discloses the differential expression of the gene coding for MAL2 protein in specific brain regions of Alzheimer's disease patients. Based on this finding, the invention provides a method for diagnosing or prognosticating Alzheimer's disease in a subject, or for determining whether a subject is at increased risk of developing Alzheimer's disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating or preventing Alzheimer's disease and related neurodegenerative disorders using the MAL2 gene and its corresponding gene products. A method of screening for modulating agents of neurodegenerative diseases is also disclosed.

Abstract: The present invention discloses the differential expression of a gene coding for SGPL1 in specific brain regions of Alzheimer's disease patients. Based on this finding, the invention provides a method for diagnosing or prognosticating a neurodegenerative disease, in particular Alzheimer's disease, in a subject, or for determining whether a subject is at increased risk of developing such a disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating or preventing Alzheimer's disease and related neurodegenerative disorders using the SGPL1 gene and its corresponding gene products. A method of screening for modulating agents of neurodegenerative diseases is also disclosed.

Abstract: The present invention discloses the differential expression of a gene coding for a GTP-binding protein from the rab-family in specific brain regions of Alzheimer's disease patients. Based on this finding, this invention provides a method for diagnosing or prognosticating a neurodegenerative disease, in particular Alzheimer's disease, in a subject, or for determining whether a subject is at increased risk of developing such a disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating or preventing Alzheimer's disease and related neurodegenerative disorders using the rab31 gene and its corresponding gene products. A method of screening for modulating agents of neurodegenerative diseases is also disclosed.

Abstract: The present invention discloses the differential expression of the TB2 gene in specific brain regions of Alzheimer's disease patients. Based on this finding, this invention provides a method for diagnosing or prognosticating a neurodegenerative disease, in particular Alzheimer's disease, in a subject, or for determining whether a subject is at increased risk of developing such a disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating or preventing Alzheimer's disease and related neurodegenerative disorders using the TB2 gene and its corresponding gene products. A method of screening for modulating agents of neurodegenerative diseases is also disclosed.

Abstract: The present invention discloses the differential expression of a cytosolic sulfotransferase in specific brain regions of Alzheimer's disease patients. Based on this finding, this invention provides a method for diagnosing or prognosticating a neurodegenerative disease, in particular Alzheimer's disease, in a subject, or for determining whether a subject is at increased risk of developing such a disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating or preventing Alzheimer's disease and related neurodegenerative disorders using a gene coding for SULT4A1. A method of screening for modulating agents of neurodegenerative diseases and recombinant animal models are also, disclosed.